NIH RePORTER
Cure8 regulatory brief
Why This Matters
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
This research aims to generate real‑world evidence and test a pragmatic trial approach to help match the right advanced therapy to each child.
Who Should Pay Attention
Pediatric Crohn’s patients and their caregivers, pediatric and adult IBD clinicians, pharmacoepidemiology researchers, and policymakers involved in pediatric drug access/coverage.
Study Snapshot
Story typeRegulatory
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This NIH-funded project will compare advanced therapies for pediatric Crohn’s disease using retrospective and prospective cohorts and a pilot pragmatic randomized trial. Aim 1 uses causal inference on a multicenter retrospective pediatric cohort to compare anti-TNF biologics versus anti-interleukin agents.
Aim 2 will expand findings with a prospective observational cohort including patient-reported outcomes. Aim 3 pilots a pragmatic randomized trial comparing two off-label advanced therapies (risankizumab and upadacitinib) in children with anti‑TNF‑refractory disease to test feasibility of real‑world trial methods.
The proposal emphasizes addressing the pediatric approval gap (only two anti‑TNF agents are FDA‑approved for children) and insurer-driven step therapy that often requires anti‑TNF failure before off‑label options. Methods include state‑of‑the‑art pharmacoepidemiologic risk adjustment and patient‑centered outcome measurement.
The pilot trial is described as feasibility-focused rather than a definitive efficacy trial. This summary is grounded in the project abstract on NIH RePORTER and describes the planned research aims and design; it does not report study results.
Keep In Mind
This is a funded research project (NIH RePORTER project record) describing planned studies — it is not a report of completed results. The pilot randomized trial is described as a feasibility study and will involve off‑label medications for children.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsBrad David Constant
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedJul 1, 2026, 12:00 AM
Content availableResearch project record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Crohn's Disease Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
Real-World Data Show Efficacy of Risankizumab in Refractory Crohn's
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...